Cystic Fibrosis

From Iusmgenetics

Contents

[edit] Cystic Fibrosis

[edit] General background information

  • 1 / 2500 newborns (Caucasian)
  • Life expectancy of only 30 years

[edit] Mode of inheritance

  • Autosomal recessive
    • Most common autosomal recessive disease of Caucasian children.
  • Pleomorphic: lungs, pancreas, endocrine, reproductive, etc.

[edit] Single important gene

  • CFTR (Cystic Fibrosis transmembrane conductance regulator)
  • 27 exons, 1480 amino acids
  • A chloride channel that is activated by cAMP
  • Over 1400 know mutations
    • 70% of cases are the deltaF508 mutant (know this: inframe, drop of one aa: phe)
    • Some pts have more than one disease causing mutation


  • Two transmembrane domains (MSD1 / 2) form a pathway for the Cl- ion.
  • Two intracellular domains (NBD1 / 2) flank the transmembrane domains and are important for processing and regulation of CFTR, respectively.
    • NBD1 and NBD2 are ATP-binding domains
  • R domain's position determines if channel is open or closed.
    • R's position is determined by phosphorylation via PKA.

[edit] Etiology

  • There is ethnic variation in the frequency of alleles and in the frequency of carriers and in the frequency of disease.
  • Some polymorphisms: some benign mutations are around in the population
  • deltaF508:
    • 70% of Caucasian disease-cuasing cases
    • A 3-base deletion: AT(CTT)T or A(TCT)TT; (Ile, Phe)
      • Last codon of 507 (aa) and first two of 508 (aa) or
      • Last two codons of 507 (aa) and first one of 508 (aa)
    • Either way, it removes the phenylalanine at position 508
    • Either way, it leaves the Ile (because ATT and ATC both code for Ile)


  • Mutations are classified (don't need to know what each does):
    • Class 1: protein is completely absent
      • Mutations in the MSD1 exon cause a splicing defect and complete absence of the protein
      • Class 1 mutations are commonly nonsense mutations
      • Includes G542X and R553X; drastically decreases mRNA levels for CFTR
    • Class 2: processing of the protein is defective
      • Mutations of the NBD1 domain cause defective processing
      • Contains deltaF508 mutation (70%)
      • Can result in abnormal protein folding and lack of CFTR at cell membrane
      • Can result in poor regulation of ORCC by CFTR
    • Class 3: regulation of the protein is defective
      • Mutations of the NBD2 domain cause defective regulation
    • Class 4: conduction of the Cl- ion is defective
      • Mutations of the MSD1 domain cause defective Cl- transport


  • CFTR is broken in cystic fibrosis.
  • CFTR's borked phenotype also affects ORCC and ENaC, too.
    • ORCC is the outwardly rectifying chloride channel
    • ENaC is the amilioride-sensitive sodium channel (epithelial Na channel)

[edit] CFTR and Intron 8 / Exon 9

  • Intron 8 of the CFTR gene contains a stretch of Thiamines (Ts)
  • As the stretch of Ts is shortened, and particularly at the length of 5, exon 9 is likely to get spliced out.
    • When 9Ts are present, 100% of mRNA transcripts include exon 9.
    • When 5Ts are present, 10% of mRNA transcripts include exon 9.
  • When CF is found in the presence of R117H, there is inefficient splicing of the 5T variant, resulting a reduced full-length transcription.
    • R117H results in functional protein and so is considered a milder form of CF.
    • High levels of R117H yield CBAVD
    • Low levels of R117H yield Chronic lung diease

[edit] Pathogenesis

  • Onset can be neonatal to adult.
  • Life expectancy is 30 years.
  • Boys live longer than girls


  • Other factors that can affect the phenotype include:
    • Severity of the CFTR polymorphisms (could be one or many, could be missense or exon loss)
    • Modifying loci exist
    • Environmental factors


  • Phenotypic variability is seen in CF.
    • There are "classic" and "nonclassic" presentations of cystic fibrosis.
    • Pancreatic sufficiency (PS) and pancreatic insufficiency (PI) can each occur in CF pts.


  • Modifier genes and environmental factors have role in severity of disease and involvement of the lungs
    • Think about genes associated with inflammation and infection
    • TGF-beta, MBL2 (mannose-binding lectin 2), others
    • Exposure to second hand smoke and how TGFB1 and CFTR respond has been shown to be important

[edit] Genotype-Phenotype Correlation

  • The genotype strongly predicts the pancreatic phenotype in cystic fibrosis
    • DeltaF508 and null alleles generate PI (pancreatic insufficiency)
    • DeltaF508 generates elevated sweat chloride
    • Partially active alleles generate PS (pancreatic sufficient) phenotypes


  • The genotype poorly predicts pulmonary phenotype in cystic fibrosis
    • DetlaF508 may cause mild to severe pulmonary disease
    • Reasons are not completely clear
    • Perhaps environmental?


  • The genotype does not correlate with meconium ileus, DIOS, liver disease, or diabetes at all in cystic fibrosis
    • DIOS is distal intestinal obstruction syndrome
    • NB: these almost never occur in the presence of a PS mutation

[edit] Phenotypic information

  • Pleomorphic in nature, affecting respiratory, gastrointestinal, and many other systems
  • Decreased life expectancy (30 years)


  • Respiratory:
    • Primary cause of death
      • Airways get congested and cause death
      • Great growing substance for bacteria
    • Chronic cough
    • Recurrent infections
    • Bronchiectasis (chronic dilation of bronchi)


  • Gastrointestinal
    • Meconium ileus (thick meconium congestion)
    • Steatorrhea (fatty stools)
    • Failure to thrive
    • Recurrent pancreatitis
    • Neonatal jaundice
    • Liver cirrhosis
    • hepatic failure is second most common cause of death


  • Other:
    • Endocrine: diabetes mellitus
    • Musculoskeletal: clubbing
    • Reproductive: absence / aplasia of vas deferens, infertility
      • NB: 95% of males are infertile
    • Integumentary: elevated sweat chloride (salty baby syndrome); >60 mEq / L (60 mmol / l)

[edit] CF in the airway epithelium

  • Healthy state:
    • Beta agonist elevates cAMP levels.
    • cAMP activates PKA.
    • PKA phosphorylates R subunit of CFTR.
    • Chloride is actively moved into the lumen of the airway.
    • Na follows passively between cell tight junctions.
    • H20 follows passively through cell membranes.
  • Disease state:
    • Beta agonist elevates cAMP levels.
    • cAMP activates PKA.
    • No CFTR is present for PKA to phosphorylate (activate).
    • Chloride cannot be moved into the lumen because CFTR is borked.
    • Na doesn't follow.
    • Very little water ends up in the lumen.


  • Reduced chloride secretion lead to a depletion of airway surface liquid (dehydration of lung surface)
  • Mucus layer of the lung may become adherent to cell surfaces and disrupt the cough and cilia dependent clearance of mucus
  • Mucus obstructs airflow, provides a niche favorable to pathogenic organisms, inhibits function of antimicrobial peptides
  • Inflammatory response releases cytokines and enzymes that damage bronchials
  • Recurrent cycles of infection, inflammation, and tissue destruction decrease amount of functional lung tissue and lead to pulmonary disease and respiratory failure
    • Sometimes the body just builds a wall around the infection and thus tissue dies.
  • Bronchiectasis
    • injury to lungs in which airways are stretched out, scarred, and can no longer move air in or out
    • Ecta means "stretched out" in Greek.
  • Lung disease is more severe when exposed to environmental factors such as cigarette smoke

[edit] CF in the pancreas

  • Deficient secretion of pancreatic enzymes
    • lipase, trypsin, chymotripsin
    • The trypsinogen test looks for elevated trypsinogen which indicates abnormal pancreatic activity ref. This test is followed up with genetic testing.
  • Loss of CFTR chloride transport into pancreatic ducts leads to the retention of exocrine enzymes in the pancreas.
  • Retention of enzymes causes fibrosis of the pancreas
  • Normal digestion can be restored through pancreatic enzyme supplements
  • 5-15% of patients are pancreatic sufficient
    • have enough pancreatic exocrine function for normal digestion have enough pancreatic exocrine function for normal digestion
    • have better growth and overall prognosis
  • Some individuals with idiopathic chronic pancreatitis carry mutations in CFTR and lack other clinical signs of CF
    • Idiopathic means the etiology is different from person to person; "we don't know why that is happening."

[edit] CF sweat phenotype

  • Sweat sodium and chloride concentrations are increased
  • Loss of CFTR leads to no reabsorbing of chloride in sweat gland duct
    • Causes reduction in electrochemical gradient that drives sodium entry across apical membrane and increased chloride concentration in sweat
  • Sweat test used to diagnose CF
    • small electrode is placed on the skin to stimulate the sweat gglands
    • amount of chloride is measured
  • > 60 mmol/L = CF
  • 40 mmol/L and 60 mmol/L are borderline
  • < 40 mmol/L are considered negative for CF
  • Sweat is normal in 1-2% of patients with CF
  • So this is clinical / phenotypic heterogenity.

[edit] CF vas deferens phenotype

  • 95% of males with CF lack vas deferens
    • Congenital Bilateral absence of the vas deferens (CBAVD)
      • Causes 2-5% of male infertility
    • Caused by problem in development of Wolffian duct
  • Females have some reduction in fertility
  • Some otherwise well males have CBAVD Some otherwise well males have CBAVD associated with mutations in CFTR
    • May be associated with heterozygous or homozygous CFTR condition

[edit] Diagnosis

  • 23 mutations are recommended for testing / screening
    • 9 are intronic mutations, (the rest are exonic mutations) 8 are missense, 4 are nonsense, and 2 are in-frame deletions (like deltaF508)

[edit] CF and Newborn Screening

  • The newborn screen for CF in Indiana measures immunoreactive trypsin (IRT).
  • If immunoreactive trypsin is high, a DNA test is done.
  • The DNA test detects 46 of the most common CFTR changes / mutations
    • The test may find 1 or more mutation in the pt.
    • Note that the implication of a positive mutation identification in CFTR is not always clear.
  • A sweat test is done to confirm a cystic fibrosis disease state in the newborn.
  • Counseling and treatment follow the screening / genetic confirmation / sweat confirmation.

[edit] Treatment

  • Therapy depends on the nature of the defect.
  • We have gotten better at treating CF over the last four decades.
  • A better understanding of the disease pathogenesis enables better therapy
  • Remember that CF is a multi-system disease (pleomorphic)
  • It has been shown that pts "do better" when treated by a multi-discipline team
  • Treat the symptoms, whether related to CFTR issues or not


  • Pulmonary therapies (problem : correction)
    • absent CFTR : use CFTR modulators and correctors
    • decreased airway surface liquid : restore ion transport
    • disrupted mucocilliary clearance : mechanically clear airway of mucus
    • colonization and chronic infection : apply antibmicrobials
    • neutrophil-dominated inflammation : apply anti-inflammatory therapy
    • Note that not all of these are realized.


  • Aminoglycoside therapy
    • First, aminoglycosides act as antibiotics
      • Effective agains pseudomonas aerruginosa (a particularly important pathogen in CF pulmonary issues).
    • Second, for nonsense mutations, high doses of aminoglycosides can increase read-through.
    • Some studies show an increase in CFTR function under high doses of aminoglycosides in nonsense mutation CF pts.
    • Gentamicin is an example of an aminoglycoside being used.
    • Note that there is some toxicity to these high doses so we must consider the balance.
    • We are looking for more effective drugs like ataluren and PTC124


  • Other treatments:
    • You don't need to know the chemicals)
    • Improve trafficking of CFTR with chaperones, correctors, and PBA (sodium-r-phenylbutyrate)
      • Chaperones: help with folding and getting to the surface of the cell
      • "Correctors"
      • PBA
    • Improve channel function with potentiators
      • Help the channel move Cl- appropriately
      • VX-770 as an example
      • Given orally
      • Shown to help for at least one known mutation: G551D

[edit] Recent research

[edit] 5 important facts

[edit] Not to be confused with

  • Several associated "monosymptomatic disorders": CBAVD (congenital bilateral absence of vas deferens), recurrent idiopathic pancreatitis


  • Congential bilateral absence of vas deferens (CBAVD)
    • Causes 2-5% of male infertility
    • 70% have >1 CF mutation
    • Can be a deltaF508 carrier
    • 33% have one CF mutation and the 5T variant
      • Note that 5T variant is on an otherwise normal locus
    • 20% have one CFTR mutation
    • 20% have two CFTR mutations
    • 1% have two 5T variants
      • Results in normal protein but a deficient amount
    • May not develop pulmonary disease at all
    • As with CF, modifier genes and environmental factors have role in severity of disease and involvement of the lungs
    • Recall R117H is associated with CBAVD and inefficient splicing of the 9th exon.

[edit] Questions and answers

Personal tools